Skip to main content

Core value dossiers for medical technologies

Essential tool to support market access and marketing efforts through the lifecycle of the product

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Establishment of the Board for Health Apps is expected in Denmark

In August 2023, the Danish Regions discussed a draft bill proposed by the Ministry of the Interior and Health for consultation. Among other initiatives, the bill suggests establishing a new Board for Health Apps (Nævnet for sundhedsapps). The Board will recommend apps based on several assessment criteria, such as evidence of effect, ease of use, reasonable price, and societal value.

Overall, Danish Regions support the establishment of the Board for Health Apps. Regions state that a national guide to health apps will give citizens and healthcare professionals a better overview of health apps that can contribute to patient treatment in the healthcare system and prevention/health promotion for citizens.

It is expected that recommendations from the Board will significantly impact the adoption of health apps. Regions recommend that the Ministry consider developing an appellation procedure for negative decisions. 

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.